Talaromycosis
Conditions
Interventions
Low-dose continuous therapy group:The patient received a 14-day course of intravenous amphotericin B liposomal therapy at a dose of 3–5 mg/kg/day.
High-dose single-treatment group:Received a single intravenous dose of amphotericin B liposome at a dosage of 10mg/kg.
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old; 2. Based on HIV screening, cases were divided into two groups: HIV-positive and HIV-positive. 3. The patient has clinical or (and) imaging manifestations of Marniffei basket disease, and the microbiological examination or pathological examination meets any one of the following: Sputum specimens, tracheal aspirate specimens, BALF specimens, lung biopsy specimens, pleural effusion, bone marrow smears, skin exudation hydraulic smears or lymph node smears were observed under a microscope after Riesch staining, and it was found that Marneffei, a typical fungus with a round or oval shape and obvious septum (often within macrophages); Sputum specimens, tracheal aspirate specimens, BALF specimens, lung biopsy specimens, pleural effusion, bone marrow smears, skin exudates, lymph node biopsy specimens or blood specimens were cultured and isolated or detected by high-throughput sequencing (NGS) or Marniffei nucleic acid testing (PCR) for Marniffei. Pathological histological examination of lung biopsy specimens, biopsy specimens of enlarged lymph nodes or lesion skin specimens revealed baskets of Marneffei, accompanied by purulent granulomatous changes, with central necrosis and extensive infiltration of mononuclear macrophages. 4. Disseminated infection: Involving two or more non-adjacent organ systems.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating patients; 2. Severe liver damage (Child-Pugh grade C); 3. Renal insufficiency (creatinine >= 5 times the upper limit of the normal value) or the need for hemodialysis; 4. Combined with other systemic fungal infections (cryptococcosis, candidiasis or mucor infection); 5. Those with active mycobacterial disease or currently undergoing chemotherapy; 6. People with mental illness or abnormal behavior; 7. Received systemic antifungal treatment within 48 hours of enrollment; 8. The researcher evaluated that there were other factors that were not suitable for enrollment (poor compliance); 9. Allergic to amphotericin B liposomes;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute kidney injury; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions, including renal dysfunction, anaemia, hypokalaemia, and hepatic dysfunction;All-cause mortality rate on day 14;Clinical response at days 7 and 14 of treatment; | — |
Countries
China
Contacts
Public ContactChao Zhuo
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed